Synopsis A recent clinical study demonstrates that sulfonylureas are highly effective and safe when used to treat KCNJ11 permanent neonatal diabetes for over 10 years. This week's ' MED FACT ' discusses a clinical trial from The Lancet Diabetes & Endocrinology, “ Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study ”. June 4, 2018.
Authors : Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE. Key Takeaways High-dose sulfonylurea therapy is an appropriate treatment for patients with KCNJ11 permanent neonatal diabetes from diagnosis. Objective Study Type Participants To evaluate the long-term efficacy and safety of sulfonylurea in patients with KCNJ11 permanent neonatal diabetes Multicentre,…
